Caribou Biosciences (CRBU) AI Stock Analysis

• Market Cap: $202.08M
• Dividend Yield: N/A
• Average Volume (3M): 1.20M
• Price to Earnings (P/E): ―
• Beta (1Y): 2.44
• Revenue Growth: -19.00%
• EPS Growth: -2.72%
• Country: US
• Employees: 147
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.30
• Shares Outstanding: 93,123,240
• 10 Day Avg. Volume: 1,354,975
• 30 Day Avg. Volume: 1,199,069
• PEG Ratio: -0.05
• Price to Book (P/B): 0.57
• Price to Sales (P/S): 14.37
• P/FCF Ratio: -0.99
• Enterprise Value/Market Cap: -0.20
• Enterprise Value/Revenue: -4.40
• Enterprise Value/Gross Profit: 1.93
• Enterprise Value/Ebitda: 0.29
• 1Y Price Target: $8.40
• Price Target Upside: 351.61% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 5
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 47 Neutral
• Price Target: $2.00 ▲(7.53% Upside)

Caribou Biosciences faces significant financial challenges, with ongoing losses and cash flow issues being the most critical factors affecting its stock score. The technical analysis indicates weak momentum, while the valuation reflects a lack of profitability. However, the positive corporate events related to promising trial results provide a potential upside, suggesting future growth opportunities.

Positive Factors

Innovative Therapies

The promising results from the ANTLER phase 1 trial highlight Caribou's potential to deliver innovative, off-the-shelf CAR-T cell therapies, enhancing its competitive edge in the biotechnology sector.

Strategic Partnerships

Caribou's strategic partnerships enable access to cutting-edge research and expand its CRISPR technology applications, fostering long-term growth and innovation in gene editing therapies.

Cash Runway

A strong cash position ensures that Caribou can sustain its operations and continue investing in R&D, critical for advancing its pipeline and achieving long-term growth.

Negative Factors

Negative Cash Flows

Persistent negative cash flows indicate ongoing financial challenges, potentially limiting Caribou's ability to invest in new projects and affecting its long-term financial health.

Revenue Decline

A significant decline in revenue growth suggests potential difficulties in market penetration or product adoption, which could hinder Caribou's ability to scale its business effectively.

Profitability Issues

Ongoing profitability issues reflect challenges in cost management and operational efficiency, which may impact Caribou's ability to achieve sustainable financial performance.

Caribou Biosciences Business Overview & Revenue Model

Company Description

Caribou Biosciences, Inc. is a biotechnology company focused on harnessing the power of CRISPR gene editing technology to develop innovative therapies for various diseases. The company operates primarily in the life sciences sector, offering products and services that enable researchers and developers to utilize CRISPR for gene editing applications. Caribou's core products include its proprietary CRISPR platform, which allows for precise genetic modifications, and it partners with academic institutions and pharmaceutical companies to advance cellular therapies and other biotechnological applications.

How the Company Makes Money

Caribou Biosciences generates revenue through multiple streams, including licensing agreements for its CRISPR technology, collaborations with pharmaceutical and biotechnology companies, and research grants. The company enters into partnerships that allow other firms to access its proprietary technologies for drug development, often receiving upfront payments, milestone payments based on development progress, and royalties on sales of resulting products. Additionally, Caribou may engage in grant-funded research projects that contribute to its income while furthering its technological advancements.

Caribou Biosciences Financial Statement Overview

Summary

Caribou Biosciences is experiencing financial difficulties with persistent losses and cash flow challenges. The income statement shows negative net profit margins, and the cash flow statement highlights negative operating and free cash flows. Despite a low debt-to-equity ratio, the company must improve profitability and cash flow generation for sustainability.

Income Statement

Caribou Biosciences shows a challenging financial performance with negative net profit margins and EBIT margins over the years, indicating ongoing losses. The TTM data reveals a slight revenue growth, but the gross profit margin is negative, suggesting cost management issues. The company needs to improve its profitability metrics to enhance its financial health.

Balance Sheet

The company's balance sheet reflects a relatively low debt-to-equity ratio, indicating conservative leverage. However, the return on equity is negative, highlighting inefficiencies in generating returns for shareholders. The equity ratio is stable, but the company must focus on improving its asset utilization and profitability to strengthen its financial position.

Cash Flow

Caribou Biosciences faces negative operating and free cash flows, with a declining free cash flow growth rate. The operating cash flow to net income ratio is negative, indicating cash flow challenges. The company needs to enhance its cash generation capabilities to support operations and future growth.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	9.29M	9.99M	34.48M	13.85M	9.60M	12.36M
Gross Profit	-21.20M	6.07M	30.95M	10.21M	8.61M	-22.06M
EBITDA	-140.02M	-162.69M	-112.53M	-95.71M	-65.61M	-35.21M
Net Income	-157.13M	-149.10M	-102.07M	-99.42M	-66.92M	-34.31M
Balance Sheet
Total Assets	194.98M	313.31M	432.21M	373.76M	442.36M	36.05M
Cash, Cash Equivalents and Short-Term Investments	147.26M	209.54M	328.83M	247.66M	375.83M	15.95M
Total Debt	25.46M	26.49M	27.11M	27.75M	259.00K	1.58M
Total Liabilities	53.14M	60.36M	63.81M	72.89M	54.53M	59.48M
Stockholders Equity	141.84M	252.95M	368.40M	300.87M	387.82M	-23.44M
Cash Flow
Free Cash Flow	-127.73M	-144.71M	-104.90M	-97.42M	-35.64M	-34.53M
Operating Cash Flow	-125.64M	-138.20M	-93.29M	-90.97M	-32.52M	-33.22M
Investing Cash Flow	100.20M	86.61M	-68.18M	-93.25M	-176.40M	6.36M
Financing Cash Flow	4.61M	16.72M	154.30M	2.13M	433.43M	1.74M

Caribou Biosciences Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.86
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CRBU, the sentiment is Negative. The current price of 1.86 is above the 20-day moving average (MA) of 1.86, below the 50-day MA of 2.20, and above the 200-day MA of 1.59, indicating a neutral trend. The MACD of -0.08 indicates Negative momentum. The RSI at 39.71 is Neutral, neither overbought nor oversold. The STOCH value of 47.31 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CRBU.

Caribou Biosciences Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CLLS	54 Neutral	$362.52M	―	-31.07%	―	158.54%	66.90%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
CRBU	47 Neutral	$202.08M	-1.22	-74.28%	―	-19.00%	-2.72%
SGMO	45 Neutral	$162.39M	―	-480.02%	―	-37.13%	40.47%
CABA	39 Underperform	$227.19M	―	-101.06%	―	―	-17.21%
VOR	33 Underperform	$226.34M	―	―	―	―	-1072.48%
ELTX	30 Underperform	$149.50M	-2.19	―	―	―	17.36%

Caribou Biosciences Corporate Events

Caribou Biosciences Reports Positive ANTLER Phase 1 Results

On November 3, 2025, Caribou Biosciences announced positive results from its ANTLER phase 1 trial, demonstrating that its allogeneic CAR-T cell therapy, vispacabtagene regedleucel (vispa-cel), shows efficacy and durability comparable to autologous CAR-T therapies in treating relapsed or refractory B cell non-Hodgkin lymphoma. The trial results highlight vispa-cel’s potential as a best-in-class therapy due to its off-the-shelf availability and favorable safety profile, which allows for outpatient administration. Additionally, the company shared data from its CaMMouflage phase 1 trial for CB-011, targeting multiple myeloma, and announced plans for a phase 3 trial for vispa-cel in large B cell lymphoma patients ineligible for transplant.